---
title: "\"Performance\" Junshi Biosciences' annual loss narrowed to 874 million RMB"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277348979.md"
description: "Junshi Biosciences announced its preliminary performance report for the year 2025, achieving total operating revenue of 2.498 billion RMB (same below), an increase of 28.2% year-on-year. The net loss narrowed from 1.281 billion RMB in the previous year to 874 million RMB, with a loss per share of 0.87 RMB"
datetime: "2026-03-01T10:03:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277348979.md)
  - [en](https://longbridge.com/en/news/277348979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277348979.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277348979.md) | [繁體中文](https://longbridge.com/zh-HK/news/277348979.md)


# "Performance" Junshi Biosciences' annual loss narrowed to 874 million RMB

Junshi Biosciences (01877.HK) announced its preliminary results for the fiscal year 2025, reporting total revenue of RMB 2.498 billion (same below), an increase of 28.2% year-on-year. The net loss narrowed from RMB 1.281 billion in the previous year to RMB 874 million, with a loss per share of RMB 0.87

### 相关股票

- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md)
- [JUNSHI BIO (01877.HK)](https://longbridge.com/zh-CN/quote/01877.HK.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md)
- [Junshi Biosciences (688180.CN)](https://longbridge.com/zh-CN/quote/688180.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-CN/quote/560600.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-CN/quote/159102.CN.md)

## 相关资讯与研究

- [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-CN/news/278713493.md)
- [Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China](https://longbridge.com/zh-CN/news/278445287.md)
- [Kintor Partners With Fonow Medicine to Commercialize KT-939 Functional Cosmetics in China](https://longbridge.com/zh-CN/news/278891486.md)
- [Fosun Pharma Unit Gets China Nod for Hematological Malignancy Drug Trial](https://longbridge.com/zh-CN/news/279052280.md)
- [Qyuns Therapeutics' Arthritis Drug Crusekitug Accepted for Review in China; Shares Jump 11%](https://longbridge.com/zh-CN/news/278491064.md)